Abstract: A support film for tape which is used for a tape, includes: a film-shaped support formed of polyurethane; and a barrier layer which includes polyvinyl alcohol and a layered inorganic compound, and which is formed on one surface of the support. The support film for tape has a degree of saponification of the polyvinyl alcohol is equal to or more than 70% and equal to or less than 95.5%.

Abstract: A medical adhesive patch, includes: a support film including a barrier layer which contains a water-soluble polymer compound and montmorillonite, and which is laminated on one surface of a support including polyurethane; an adhesive layer which contains a medicine and a plasticizer, and which is laminated on a barrier layer of the support film, the medical adhesive patch has a percentage content of montmorillonite in the barrier layer is equal to or more than 2 percent by weight and equal to or less than 22 percent by weight.

Abstract: Provided is a transdermal preparation, which is capable of long-term (1-day to 7-day) release of a basic drug from a preparation, continuously and at a consistent concentration; shows little reduction over time in the drug content, even if multiple drugs are contained in the preparation; and is produced by a simple process. The transdermal preparation comprises a substrate, and an adhesive layer containing a basic drug and a water-soluble polymer.

Abstract: A medical adhesive patch includes: a support film including a barrier layer which contains polyvinyl alcohol and a layered inorganic compound, and which is laminated on one surface of a support including polyurethane; an adhesive layer which contains a medicine, and which is laminated on the barrier layer of the support film, a degree of saponification of the polyvinyl alcohol is equal to or more than 70% and equal to or less than 95.5%.

Abstract: An adhesive preparation comprising a stretchable support and an adhesive layer laminated on at least one side of the support, wherein the stretchable support comprises a interlock woven fabric subjected to crimping processing, the adhesive layer contains 10% by mass or more of methyl salicylate with respect to the total mass of the layer, the whole adhesive preparation has moisture permeability of 1 to 350 g/m2·24 hr measured at a temperature of 40° C. and a relative humidity of 90%, and the methyl salicylate has a plasma AUC0-24 ranging from 3.0 to 60.0 ng·hr/mL in terms of a mean±standard deviation, and salicylic acid as a metabolite of the methyl salicylate has a plasma AUC0-24 ranging from 5000 to 13000 ng·hr/mL in terms of a mean±standard deviation, when the adhesive preparation is applied to a human skin for 8 hours such that an application amount of the adhesive layer applied is 50 to 300 g/m2 and a contact area is 280 cm2.

Abstract: A transdermally absorbable preparation that even when a drug with poor solubility in a base is added in high concentration, is stable over time and can suppress crystallization of the drug, excelling in transdermal absorbability. There is provided a transdermally absorbable preparation, comprising a base and, added thereto, at least composite particles which are composed of a silicate compound and an organic acid and a drug.

Abstract: A patch formulation for external use where a basic drug, an organic acid and an organic acid salt are combined as essential components is disclosed. The basic drug is preferably in the form of its acid addition salt. The organic acid is preferably a carboxylic acid having carbon atoms of 2 to 7, and more preferably at least one acid selected from the group consisting of acetic, lactic, tartaric, citric, malic, benzoic and salicylic acids. The organic acid salt is preferably a metal salt of a carboxylic acid, and more preferably sodium acetate.

Abstract: It is intended to provide a transdermal drug administration apparatus having microneedles, which is capable of piercing the skin by a simple procedure in the transdermal administration of a biologically active substance (drug) and allows rapid absorption of the biologically active substance. The present apparatus comprises a microneedle device (50) comprising a microneedle substrate (53) having a plurality of microneedles (51) capable of piercing the skin, an absorbent (11) disposed thereon, the absorbent (11) comprising a material capable of absorbing a liquid, and a dissolving solution reservoir (18) disposed on the absorbent (11), the dissolving solution reservoir (18) containing a dissolving solution (16) for dissolving a drug and being capable of disrupting a diaphragm (20) provided the dissolving solution reservoir (18) and the absorbent (11) by pressing. A coating containing a dry drug is disposed on the microneedles (51) and/or the microneedle substrate (53).

Abstract: An array 1 with microprotrusions comprises a base 2 and tapered microprotrusions 3 each disposed on the base 2 and tapering down toward the tip from the bottom. Letting a distance from the tip to the bottom on an arbitrary side of each microprotrusion 3 as a and letting the length of a second line segment prepared by projecting a first line segment representing the distance a onto the base 2 as b, a relationship of 1.0<(a/b)?7.5 holds.

Abstract: An array 1 provided with microprotrusions comprises a base 2 and tapered microprotrusions 3 each disposed on the base 2 and tapering down toward the tip from the bottom. Letting a distance from the tip to the bottom on an arbitrary side of each microprotrusion 3 as a and letting the length of a second line segment prepared by projecting a first line segment representing the distance a onto the base 2 as b, a relationship of 1.0<(a/b)?7.5 holds.

Abstract: Provided is a skin irritation suppressant for transdermal preparations, having a sufficient reduction effect of skin irritation due to a drug. Also provided is a transdermal preparation comprising the skin irritation suppressant. One embodiment of the invention is a skin irritation suppressant for suppressing the skin irritation due to a drug and a pharmaceutical ingredient to be used in a transdermal preparation other than the drug, the skin irritation suppressant comprising a sterol compound selected from the group consisting of cholesterol, cholesterol derivatives and cholesterol analogs, and the drug is one or more basic drugs selected from the group consisting of tolterodine, asenapine, bisoprolol, risperidone, nicotine and citalopram, and their pharmaceutically acceptable salts.

Abstract: Provided is a transdermal preparation having low skin irritation as well as a sufficient skin permeability rate of donepezil, which comprises one or more drugs selected from donepezil and pharmaceutically acceptable salts thereof. Also provided are a manufacturing method thereof, and a method for reducing skin irritation of a transdermally absorbable donepezil-containing preparation. An embodiment is a transdermal preparation comprising one or more drugs selected from donepezil and pharmaceutically acceptable salts thereof, and a skin irritation-reducing agent.

Abstract: Provided is an adhesive patch including a stretchable support and an adhesive layer laminated on at least one side of the support, wherein the stretchable support comprises a woven fabric knitted in stockinette stitch on both sides having two or more rows of crimped polyethylene terephthalate multifilament yarns, the adhesive layer contains 25 to 50% by mass of a liquid organic ingredient and 25 to 50% by mass of a thermoplastic elastomer based on the total mass of the layer and contains 10% by mass or more of methyl salicylate as the liquid organic ingredient based on the total mass of the layer, and the storage elastic modulus (G?) of the adhesive layer is 30000 to 75000 Pa at 10 rad/s and 37° C.

Abstract: The present invention provides a micro-needle device that includes a substrate, a micro-needle provided on the substrate, and a physiologically active composition deposited on the micro-needle and/or the substrate. In the micro-needle device, the physiologically active composition contains: at least one polyhydric alcohol selected from glycerin, ethylene glycol, propylene glycol and 1,3-butylene glycol; and a physiologically active substance, and contains substantially no water.

Abstract: An object of the present invention is to efficiently inject a drug (physiologically active substance). Therefore, a micro-needle device 1 comprises a base plate 2 and a micro-needle 3 installed on the base plate 2. A coating agent containing the physiologically active substance is coated at least at a part of the micro-needle 3, and a coating range thereof is 100 to 230 ?m including the top of the micro-needle 3. A load due to the energy of 0.2 to 0.7 J/cm2 is applied to the micro-needle device 1 which is in contact with the skin.

Abstract: The present invention provides a patch having a backing and a pressure-sensitive adhesive layer on the backing, wherein the pressure-sensitive adhesive layer contains a pressure-sensitive adhesive base composed of a polymer having a hydroxyl group, a drug, polyvinylpyrrolidone and a multivalent metal chloride.

Abstract: A transdermal preparation comprising a multivalent metal chloride, a basic drug having an amino group, and an ester group-containing base material, is useful because of its excellent drug content stability.